CliffBio
biologic

Tevimbra

tislelizumab-jsgr

Loss of exclusivityMarch 2036projected — 12-year biologic exclusivity estimate
CompanyBeiGene →View the full company profile on CliffBio

Drug detail

Brand nameTevimbra
Active ingredienttislelizumab-jsgr
Strength100MG/10ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalMarch 2024
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tevimbra patent cliff — loss of exclusivity March 2036 | CliffBio